Profile data is unavailable for this security.
About the company
AbbVie Inc. is a global, diversified research-based biopharmaceutical company. It is engaged in research and development, manufacturing, commercialization and sale of medicines and therapies. Its product portfolio includes Immunology, Oncology, Aesthetics, Neuroscience, Eye Care and Other Key Products. Immunology products include rheumatology, dermatology and gastroenterology. Oncology products include Imbruvica, Venclexta/Venclyxto, Elahere and Epkinly. Aesthetics portfolio consists of facial injectables, plastics and regenerative medicine, body contouring, and skincare products. Its Neuroscience products include Botox Therapeutic, Vraylar, Duopa and Duodopa, Ubrelvy, and Qulipta. Eye Care products include Ozurdex, Lumigan/Ganfort, Alphagan/Combigan, Restasis, and other eye care. Other key products include Mavyret/Maviret, Creon, and Linzess/Constella. Its investigational candidate, bretisilocin, is for the treatment of patients with moderate-to-severe major depressive disorder (MDD).
- Revenue in USD (TTM)61.16bn
- Net income in USD4.19bn
- Incorporated2012
- Employees57.00k
- LocationAbbVie Inc1 N Waukegan RdNORTH CHICAGO 60064United StatesUSA
- Phone+1 (847) 932-7900
- Fax+1 (302) 655-5049
- Websitehttps://www.abbvie.com/
Mergers & acquisitions
| Acquired company | ABBV:NYQ since announced | Transaction value |
|---|---|---|
| West Pharmaceutical Services Inc-SmartDose | 6.26% | 112.50m |
| Capstan Therapeutics Inc | 28.28% | 2.10bn |
Peer analysis
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Amgen Inc | 36.75bn | 7.71bn | 207.92bn | 31.50k | 27.09 | 24.00 | 16.09 | 5.66 | 14.24 | 14.24 | 67.87 | 16.07 | 0.4029 | 1.62 | 4.49 | 1,166,698.00 | 8.45 | 7.90 | 11.52 | 10.18 | 70.89 | 71.81 | 20.98 | 20.55 | 0.8958 | 15.77 | 0.8631 | 74.82 | 9.95 | 7.65 | 88.53 | 1.20 | 25.03 | 8.27 |
| Merck & Co Inc | 65.01bn | 18.25bn | 300.17bn | 75.00k | 16.69 | 5.71 | 12.44 | 4.62 | 7.28 | 7.28 | 25.93 | 21.26 | 0.512 | 2.33 | 5.90 | 866,813.30 | 14.38 | 11.33 | 18.53 | 14.83 | 77.14 | 74.45 | 28.09 | 21.08 | 1.30 | 27.85 | 0.4837 | 60.05 | 1.31 | 9.38 | 6.64 | 32.21 | -1.47 | 5.49 |
| AbbVie Inc | 61.16bn | 4.19bn | 414.21bn | 57.00k | 99.25 | -- | 33.15 | 6.77 | 2.36 | 2.36 | 34.50 | -1.85 | 0.4545 | 3.80 | 5.20 | 1,072,983.00 | 3.15 | 5.27 | 4.53 | 7.07 | 71.62 | 69.82 | 6.92 | 12.86 | 0.557 | 7.90 | 1.05 | 146.03 | 8.57 | 5.95 | -1.23 | -1.68 | 8.75 | 7.10 |
| Johnson & Johnson | 94.19bn | 26.80bn | 599.00bn | 138.20k | 22.51 | 7.34 | 17.46 | 6.36 | 11.04 | 11.04 | 38.78 | 33.86 | 0.4967 | 2.27 | 5.88 | 681,570.20 | 14.13 | 9.88 | 19.50 | 13.58 | 67.98 | 69.12 | 28.46 | 20.93 | 0.7655 | -- | 0.3702 | 65.67 | 6.05 | 2.67 | 97.67 | 14.04 | 7.62 | 5.25 |
| Holder | Shares | % Held |
|---|---|---|
| The Vanguard Group, Inc.as of 31 Dec 2025 | 162.62m | 9.20% |
| BlackRock Fund Advisorsas of 31 Dec 2025 | 95.07m | 5.38% |
| SSgA Funds Management, Inc.as of 31 Dec 2025 | 80.94m | 4.58% |
| Geode Capital Management LLCas of 31 Dec 2025 | 44.63m | 2.53% |
| JPMorgan Investment Management, Inc.as of 31 Dec 2025 | 34.27m | 1.94% |
| Norges Bank Investment Managementas of 31 Dec 2025 | 25.67m | 1.45% |
| Capital Research & Management Co. (Global Investors)as of 31 Dec 2025 | 25.41m | 1.44% |
| Charles Schwab Investment Management, Inc.as of 31 Dec 2025 | 25.17m | 1.42% |
| Morgan Stanley Smith Barney LLC (Investment Management)as of 31 Dec 2025 | 21.42m | 1.21% |
| Northern Trust Investments, Inc.(Investment Management)as of 31 Dec 2025 | 18.85m | 1.07% |
